Progranulin therapy refers to therapeutic strategies designed to restore progranulin (PGRN) levels in the central nervous system to treat frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions associated with progranulin deficiency. Progranulin is a secreted glycoprotein encoded by the GRN gene that plays critical roles in neuronal survival, lysosomal function, synaptic plasticity, and inflammation modulation.
Loss-of-function mutations in GRN cause haploinsufficiency, resulting in approximately 50% reduction in progranulin levels, which leads to frontotemporal dementia (FTD-GRN) characterized by TDP-43 proteinopathy. Therapeutic approaches aim to boost progranulin expression or deliver functional progranulin protein to prevent or slow neurodegeneration.
GRN mutations causing FTD are typically null alleles that result in haploinsufficiency:
- Mechanism: ~50% reduction in progranulin protein levels
- Pathology: TDP-43 positive inclusions (type A) throughout the brain
- Clinical phenotypes: Behavioral variant FTD, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy
- Age of onset: Typically 45-65 years, with high penetrance
Progranulin deficiency leads to:
- Lysosomal dysfunction: Impaired lysosomal biogenesis and function
- Increased neuroinflammation: Enhanced microglial activation
- TDP-43 mislocalization: Cytoplasmic TDP-43 inclusions
- Neuronal vulnerability: Reduced neurotrophic support
- Impaired autophagy: Disrupted protein clearance pathways
Progranulin therapy aims to:
- Restore physiological progranulin levels to above the therapeutic threshold
- Improve lysosomal function in neurons and microglia
- Reduce neuroinflammation through immunomodulatory effects
- Protect against TDP-43 pathology
- Support neuronal survival through neurotrophic activity
Recombinant adeno-associated virus (AAV) delivery of the GRN gene offers sustained progranulin expression:
- PBFT02: AAV-based gene therapy delivering GRN to the CNS; currently in Phase 1b for FTD-GRN patients
- AVB-101: AAV gene therapy targeting bilateral intrathalamic infusion; in Phase 1/2 trials for FTD-GRN
- Vector optimization: Use of neuronal-specific promoters (Synapsin, CamKII) for targeted expression
- Delivery methods: Intracerebral, intracisterna magna (ICM), or intrathalamic administration
Advantages: Long-lasting expression, single-dose potential
Challenges: Invasive delivery, immune response to viral vectors, achieving adequate brain distribution
Direct delivery of recombinant progranulin protein:
- FRM-0334: Recombinant progranulin protein; studied in Phase 1/2 trials for FTD-GRN
- DNL593: Engineered progranulin variant with enhanced CNS penetration; in clinical development
Advantages: Direct protein delivery, measurable pharmacodynamics
Challenges: Blood-brain barrier penetration, short half-life, repeated dosing requirements
Oral pharmacological approaches to increase endogenous progranulin:
- LY3884963: Small molecule progranulin enhancer; in Phase 1/2 trials for FTD-GRN
- VES001: Oral progranulin-boosting compound; in multiple clinical trials for asymptomatic and symptomatic GRN carriers
- Mechanism: Upregulation of GRN gene expression through transcriptional activation
- Alternative targets: Inhibition of progranulin degradation pathways
Advantages: Oral bioavailability, non-invasive delivery
Challenges: Achieving adequate CNS exposure, mechanism validation
ASO-based approaches to modulate GRN expression:
- Target: Increase GRN mRNA translation or reduce degradation
- Delivery: Intrathecal administration to reach CNS
- Status: Preclinical development stage
Cell platforms for progranulin delivery:
- Engineered mesenchymal stem cells (MSCs): Modified to secrete progranulin
- Encapsulated cell biodelivery (ECB): Implantable devices with engineered cells
- Status: Preclinical/early translational stage
| Trial ID |
Therapy |
Phase |
Indication |
Status |
| NCT04885114 |
PBFT02 (gene therapy) |
Phase 1b |
FTD-GRN |
Recruiting |
| NCT06064890 |
AVB-101 (gene therapy) |
Phase 1/2 |
FTD-GRN |
Recruiting |
| NCT05549648 |
LY3884963 (small molecule) |
Phase 1/2 |
FTD-GRN |
Recruiting |
| NCT05864330 |
VES001 (small molecule) |
Multiple |
FTD-GRN |
Recruiting |
| NCT05725190 |
DNL593 (protein therapy) |
Phase 1/2 |
FTD-GRN |
Recruiting |
Gene Therapy Trials:
- PBFT02: Phase 1b open-label, multicenter study assessing safety and pharmacodynamic effects of PBFT02 delivered into the cisterna magna in adults with FTD and GRN or C9ORF72 mutations
- AVB-101: Phase 1/2 study evaluating safety and preliminary efficacy administered by bilateral intrathalamic infusion in subjects with FTD-GRN
Small Molecule Trials:
- LY3884963: Phase 1/2 ascending dose study to evaluate safety and effects on progranulin levels in FTD-GRN patients
- VES001: Multiple studies including asymptomatic GRN mutation carriers and symptomatic FTD-GRN patients
Protein Therapy Trials:
- DNL593: Study to evaluate safety, tolerability, PK, and PD in healthy participants and FTD-GRN patients
- FRM-0334: Completed Phase 1 study evaluating plasma progranulin changes
- Plasma progranulin: Primary pharmacodynamic biomarker
- CSF progranulin: CNS exposure indicator
- Emerging: CSF/serum neurofilament light chain (NfL) as neurodegenerative marker
- Neurofilament light chain (NfL): Marker of neuronal injury
- Neuroimaging: MRI volumetric measures of brain atrophy
- Cognitive assessments: CDR, FBI, CAMCOG for FTD
- Pre-symptomatic carriers: Prevention trials in asymptomatic GRN mutation carriers
- Biomarker-driven enrollment: Use of progranulin levels and NfL for patient selection
- Combination endpoints: Clinical and biomarker outcomes
- Grn knockout mice: Show increased neuroinflammation, lysosomal abnormalities, and age-dependent neurodegeneration
- AAV-Grn delivery: Rescues behavioral deficits and neuropathology in Grn-deficient mice
- Protein delivery: Recombinant progranulin improves lysosomal function in models
- Progranulin overexpression protects against excitotoxicity and oxidative stress
- AAV-mediated GRN delivery restores progranulin levels and improves survival in animal models
- Small molecule GRN enhancers increase progranulin expression in vitro and in vivo
- Combination approaches (gene therapy + small molecules) show synergistic effects
Primary indication for progranulin therapy:
- Targets the underlying genetic cause
- Aims to prevent or slow TDP-43 pathology
- May be most effective in pre-symptomatic carriers
GRN mutations can co-occur with ALS:
- Overlapping TDP-43 pathology
- Progranulin therapy may benefit ALS patients with GRN mutations
- Clinical trials include FTD-GRN and ALS patients
Homozygous GRN mutations cause NCL:
- More severe progranulin deficiency
- Potential for protein/gene therapy
- Research stage
- Alzheimer's disease: Progranulin may have protective effects; being investigated
- Parkinson's disease: GRN variants associated with PD risk; therapeutic potential unclear
- Psychiatric disorders: Progranulin implicated in depression and schizophrenia
¶ Challenges and Considerations
- Blood-brain barrier: CNS delivery remains the primary challenge
- Vector distribution: Achieving uniform brain coverage with AAV
- Dosing: Determining optimal therapeutic window
- Immune response: Pre-existing antibodies to AAV vectors
- Off-target effects: Potential for overexpression-related toxicity
- Long-term expression: Durability and safety over years
- Need for validated CNS biomarkers: Beyond plasma progranulin
- Disease progression markers: For clinical trial endpoints
- Patient stratification: Identifying optimal responders